Esomeprazole 24 Hour Now OTC

Esomeprazole 24 Hour Now OTC

The recent FDA approval for AstraZeneca’s Nexium 24 hour, or Esomeprazole, was exciting news for the pharmaceutical world. With over sixty million Americans suffering from heartburn at least once a month the advent of a 24 hour treatment that is easy to access is relieving. As an OTC or over the counter treatment for gastroesophageal reflux disease {GERD} Esomeprazole is effectual at alleviating burdensome symptoms such as pain, excess acid and burning of the esophagus and gastrointestinal tract. Sales of Nexium {Esomeprazole} soared in 2013, reaching $3.9 billion dollars. The recent OTC approval of Esomeprazole by the FDA is poised to generate a sizable profit in 2014.


As an effective medication in the proton pump inhibitor class Esomeprazole works by decreasing the amount of acid created in the stomach. Patients suffering from GERD, Zollinger-Ellison syndrome and ulcers of the stomach due to H. pylori find significant relief when taking Esomeprazole. The newly approved over the counter Esomeprazole stands to aid a greater number of patients and help to remedy the plethora of GERD complications, including chest pain, asthma, bloating, nausea, coughing, dental erosion and hiccups. There are currently a wide array of situational causes for acid reflux, like pregnancy, a hiatal hernia, peptic ulcers, alcoholism, smoking and obesity. With easier access to an OTC remedy patients will be more likely to treat their symptoms of acid reflux with Esomeprazole 24.

Fifteen million Americans report that they have symptoms of GERD, particularly heartburn, every single day. While this debilitating condition affects people of all ages it is most common in adults over the age of forty. Addtionally, the National Digestive Diseases Information Clearinghouse reports that patients with GERD receive over one million prescriptions for medication each year. These patients will not only benefit from Esomeprazole 20 milligrams 24 hour but they will also find an easier path to relief with this newly approved over the counter treatment. The patent for Prilosec I.V., another brand name Esomeprazole product expires in May 2014.

LGM Pharma supplies the API Esomeprazole CAS# 119141-88-7, for research and development purposes. Clients can be assured of quality API products and continuous support throughout the R&D process.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e) +A13(1). Any patent infringement and resulting liability is solely at buyer risk.



  • Share:

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service